Pediatric hematology and oncology
-
Pediatr Hematol Oncol · Jan 2000
Pediatric hematology and oncology at the University Children's Hospital, Basel, Switzerland.
The department offers the management and research of benign and malignant pediatric hematology and oncology at a comparable European standard. It serves as a referring department for BMT, thoracic and visceral pediatric surgery, and pediatric orthopedic surgery and is equipped with all facilities of modern oncology and surgery. Psychooncology is a continuing interest at our department and may help children and their families to better understand and accept their situation and to receive the support necessary for coping with the threat of malignant diseases. Our department aims at practicing a highly sophisticated communication culture essential for a multidisciplinary approach to the child with cancer, representing a central condition for the success of the treatment of malignant diseases.
-
Pediatr Hematol Oncol · Jan 2000
Use of alternative therapy among pediatric oncology patients in Taiwan.
Both alternative medicine and western medicine have been commonly used to treat pediatric cancer patients in Taiwan. Each has its own intrinsic strengths and weaknesses and they can be complementary. Little is known about medical help-seeking behaviors of parents of pediatric cancer patients, especially those related to alternative therapies. ⋯ Such practices generally occur without medical guidance from oncologists, largely because of poor interactions between parents and oncologists. Future efforts should be made to encourage both parents and oncologists to discuss this issue. Nurses may serve as mediators by developing mutual trust and a sharing relationship between these groups.
-
Pediatr Hematol Oncol · Nov 1999
Ewing's sarcoma: prognosis and survival in Mexican children from a single institution.
A retrospective analysis of 55 patients with Ewing's sarcoma from an institution in Mexico was done between 1980 and 1993. The ages ranged between 2 and 16 years (mean 9.78); 39 were male and 16 female. The most frequent primary sites were in the humerus in 13 of 55 patients (23.6%), followed by the pelvis in 10 out of 55 (18%). ⋯ Patients in regimen 3 had a DFS of 47% at 36 months of follow-up compared to 20 and 25% for patients in regimens 1 and 2, respectively (p = .01). In those with trunk presentation the DFS was of 25% and in those with presentation in the extremities DFS was 50% (p = .01). Patients with pulmonary metastasic disease at diagnosis have a DFS of 20% in comparison to those without (44%) (p = .00061).
-
Pediatr Hematol Oncol · Jul 1999
The total care unit for pediatric hematology and oncology, Princess Margaret Hospital for Children, Perth, Australia.
The total care unit for the treatment of pediatric hematology/oncology in Perth, Australia is so named to embody the philosophy of multidisciplinary care of children and their families. Where possible, patients are treated according to randomized controlled trials of the large cooperative Children's Cancer Group. ⋯ Hemopoietic stem cell transplantation is managed within the unit, as well as treatment of a range of non-malignant hematological disorders. Long-term follow-up of survivors of childhood cancer is coordinated from the unit.
-
Pediatr Hematol Oncol · May 1999
Treatment of pediatric B-cell non-Hodgkin's lymphomas at the Motol Hospital in Prague, Czech Republic: results based on the NHL BFM 90 protocols.
Malignant non-Hodgkin's lymphomas (NHL) of childhood and adolescence are a heterogeneous group of diseases originating from the lymphoid cells. Unlike adults with non-Hodgkin's lymphoma, children typically have extranodal disseminated disease of high grade (Burkitt's lymphoma, large cell lymphoma, or lymphoblastic lymphoma). This study was conducted to determine the feasibility of treating children in the Czech Republic with B-cell non-Hodgkin's lymphomas according to very intensive protocols based on the German Berlin Frankfurt Munster (BFM) NHL 90 study. ⋯ Treatment results were not identical between NHL subtypes, with large cell lymphoma patients doing significantly better (pEFS 90%, p = .008). The use of protocols based on BFM 90 study was feasible at this center. The treatment results are approximately 10% lower than those reported by BFM investigators, but comparable to results from other centers.